Riders · Department of State Health Services · Article II: Health and Human Services
HIV Vendor Drug Rebates
Rider 17 in the 2026-27 Act, page II-29
2028-29 request. Department of State Health Services's request has a row with this rider's number. What that row asks could not be checked, so it is not shown. The agency's request.
Through the session
- 2024-25 Act In current law rider 18
- Introduced (Senate) Amended rider 17
- Introduced (House) Amended rider 17
- Senate substitute Amended rider 17
- House substitute Unchanged rider 17
- House passed Unchanged rider 17
- Conference Unchanged rider 17
- 2026-27 Act Unchanged rider 17
Pick any two steps to compare their wording.
What changed in the text
Introduced (Senate) → Senate substitute: 6 passages changed.
Removed words are struck through; added words are underlined. Sources: Introduced (Senate) · Senate substitute.
Every version: numbers, statuses and source pages
| Version | Rider | Against the version before | Against the current budget | Source |
|---|---|---|---|---|
| 2024-25 ActGeneral Appropriations Act, 2024-25 Biennium | 18 | First version | — | Page II-30 |
| Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) | 17 was 18 | Amended | — | Page II-33 |
| Introduced (House)House Bill 1 as introduced (LBB recommended, House) | 17 was 18 | Amended | — | Page II-33 |
| Senate substituteCommittee Substitute for Senate Bill 1 | 17 | Amended | Amended | Page II-27 |
| House substituteHouse Committee Substitute for Senate Bill 1 | 17 | Unchanged | Amended | Page II-27 |
| House passedSenate Bill 1 as passed the second house | 17 | Unchanged | Amended | Page II-27 |
| ConferenceConference Committee Report for Senate Bill 1 | 17 | Unchanged | Amended | Page II-28 |
| 2026-27 ActGeneral Appropriations Act, 2026-27 Biennium | 17 | Unchanged | Amended | Page II-29 |
Full text of each wording
Senate substitute, Conference, 2026-27 Act
Source, page II-29HIV Vendor Drug Rebates. Included in amounts appropriated above in Strategy A.2.2, HIV/STD Prevention, is all rebate revenue earned via the HIV Medication Program and deposited under the Comptroller's Revenue Object Code No. 3552, estimated to be $ 3,993,952 in HIV Vendor Drug Rebates Account No. 8149 (Other Funds) each fiscal year of the biennium to administer the HIV/STD program in accordance with the applicable federal law. Any unexpended and unobligated balances remaining as of August 31, 2025, in HIV Vendor Drug Rebates Account No. 8149 (Other Funds), are appropriated for the fiscal year beginning September 1, 2025, for the same purpose. Any unexpended balances remaining from amounts appropriated in HIV Vendor Drug Rebates Account No. 8149 (Other Funds) in this rider as of August 31, 2026, are appropriated for the fiscal year beginning September 1, 2026, for the same purpose. For expenditures which may be funded with rebates, General Revenue Fund appropriations, or General Revenue-Dedicated Fund appropriations, rebates should be expended first to the extent possible while ensuring the Maintenance of Effort is met with General Revenue Fund expenditures. No later than November 1 of each fiscal year, DSHS shall report to the Legislative Budget Board the amount of unexpended balances of rebate revenue from the previous fiscal year and the agency's planned use of these balances.
House substitute, House passed
Source, page II-27HIV Vendor Drug Rebates. Included in amounts appropriated above in Strategy A.2.2, HIV/STD Prevention, is all rebate revenue earned via the HIV Medication Program and deposited under the Comptroller's Revenue Object Code No. 3552, estimated to be $3,993,952 in HIV Vendor Drug Rebates Account No. 8149 (Other Funds) each fiscal year of the biennium to administer the HIV/STD program in accordance with the applicable federal law. Any unexpended and unobligated balances remaining as of August 31, 2025, in HIV Vendor Drug Rebates Account No. 8149 (Other Funds), are appropriated for the fiscal year beginning September 1, 2025, for the same purpose. Any unexpended balances remaining from amounts appropriated in HIV Vendor Drug Rebates Account No. 8149 (Other Funds) in this rider as of August 31, 2026, are appropriated for the fiscal year beginning September 1, 2026, for the same purpose. For expenditures which may be funded with rebates, General Revenue Fund Appropriations, or General Revenue-Dedicated Fund Appropriations, rebates should be expended first to the extent possible while ensuring the Maintenance of Effort is met with General Revenue Fund expenditures. No later than November 1 of each fiscal year, DSHS shall report to the Legislative Budget Board the amount of unexpended balances of rebate revenue from the previous fiscal year and the agency's planned use of these balances.
Introduced (House)
Source, page II-33HIV Vendor Drug Rebates. Included in amounts appropriated above in Strategy A.2.2, HIV/STD Prevention, is all rebate revenue earned via the HIV Medication Program and deposited under the Comptroller's Revenue Object Code No. 3552, estimated to be $ 3,993,952 in HIV Vendor Drug Rebates Account No. 8149 (Other Funds) each fiscal year of the biennium to administer the HIV/STD program in accordance with the applicable federal law. Any unexpended and unobligated balances remaining as of August 31, 202 5, in HIV Vendor Drug Rebates Account No. 8149 (Other Funds), are appropriated for the fiscal year beginning September 1, 202 5, for the same purpose. Any unexpended balances remaining from amounts appropriated in HIV Vendor Drug Rebates Account No. 8149 (Other Funds) in this rider as of August 31, 202 6, are appropriated for the fiscal year beginning September 1, 202 6, for the same purpose. For expenditures which may be funded with rebates, General Revenue Fund Appropriations, or General Revenue-Dedicated Fund Appropriations, rebates should be expended first to the extent possible while ensuring the Maintenance of Effort is met with General Revenue Fund expenditures. No later than November 1 of each fiscal year, DSHS shall report to the Legislative Budget Board the amount of unexpended balances of rebate revenue from the previous fiscal year and the agency's planned use of these balances.
Introduced (Senate)
Source, page II-33HIV Vendor Drug Rebates. Included in amounts appropriated above in Strategy A.2.2, HIV/STD Prevention, is all rebate revenue earned via the HIV Medication Program and deposited under the Comptroller's Revenue Object Code No. 3552, estimated to be $ 3,993,952 in HIV Vendor Drug Rebates Account No. 8149 (Other Funds) each fiscal year of the biennium to administer the HIV/STD program in accordance with the applicable federal law. Any unexpended and unobligated balances remaining as of August 31, 202 5, in HIV Vendor Drug Rebates Account No. 8149 (Other Funds), are appropriated for the fiscal year beginning September 1, 202 5, for the same purpose. Any unexpended balances remaining from amounts appropriated in HIV Vendor Drug Rebates Account No. 8149 (Other Funds) in this rider as of August 31, 202 6, are appropriated for the fiscal year beginning September 1, 202 6, for the same purpose. For expenditures which may be funded with rebates, General Revenue Fund appropriations, or General Revenue-Dedicated Fund appropriations , rebates should be expended first to the extent possible while ensuring the Maintenance of Effort is met with General Revenue Fund expenditures. No later than November 1 of each fiscal year, DSHS shall report to the Legislative Budget Board the amount of unexpended balances of rebate revenue from the previous fiscal year and the agency's planned use of these balances.
2024-25 Act
Source, page II-30HIV Vendor Drug Rebates. Included in amounts appropriated above in Strategy A.2.2, HIV/STD Prevention, is all rebate revenue earned via the HIV Medication Program and deposited under the Comptroller's Revenue Object Code No. 3552, estimated to be $19,720,975 in HIV Vendor Drug Rebates Account No. 8149 (Other Funds) each fiscal year of the biennium to administer the HIV/STD program in accordance with the applicable federal law. Any unexpended and unobligated balances remaining as of August 31, 2023, in HIV Vendor Drug Rebates Account No. 8149 (Other Funds), are appropriated for the fiscal year beginning September 1, 2023, for the same purpose. Any unexpended balances remaining from amounts appropriated in HIV Vendor Drug Rebates Account No. 8149 (Other Funds) in this rider as of August 31, 2024, are appropriated for the fiscal year beginning September 1, 2024, for the same purpose. For expenditures which may be funded with rebates, General Revenue Funds, or General Revenue-Dedicated Funds, rebates should be expended first to the extent possible while ensuring the Maintenance of Effort is met with General Revenue expenditures. No later than November 1 of each fiscal year, DSHS shall report to the Legislative Budget Board the amount of unexpended balances of rebate revenue from the previous fiscal year and the agency's planned use of these balances.